fda bans compounded semaglutide GLP-1 ban: What providers need to know The FDA's Decision to Ban

The format point matters clinically

It is for understanding the options, not a protocol to follow on your own

An intra-colonic injection of 180 mmol l 1 propionate (a total dose of ~0.45 mmol) vs saline control (matched for sodium content and pH) in anaesthetised rats resulted in a significant rise in circulating plasma PYY and GLP-1 levels (two-way ANOVA, effect of treatment P =0.024 and P =0.023, respectively)

possible ADA session expansion) Q4 2026: NDA submission to FDA 2027: Standard FDA review (610 months) If Lilly uses the Commissioner's National Priority Voucher the same accelerated pathway that compressed orforglipron's review to 50 days retatrutide approval could land as early as Q1 2027

Therefore, we engineered a chimeric protein by fusing GLP-1 to an HSA-binding DARPin with a high affinity for albumin that takes advantage of the extended plasma circulation of HSA to develop a long-acting variant of GLP-1

This represents a potential advantage over pure GLP-1 agonists